{"ticker": {"uuid": "76da2cf7-50cc-4dc4-b51d-157448b7cb97", "symbol": "BRM", "name": "Bristol-Myers Squibb Company", "exchange": "GER", "country": "DE", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?", "summary": "Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio \u2014 including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy \u2014 is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r", "url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T18:36:00+00:00", "published_display": "12 Aug 2026 18:36", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.246, "duplicate_count": 1, "topics": ["Immuno Oncology", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "Is Bristol Myers\u2019 US$2.3 Billion Houston Manufacturing Campus Altering The Investment Case For BMY?", "summary": "Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about 2,000 construction and indirect roles through 2030. This facility's flexible, automation-ready design and alignment with the company's broader US$40.00 billion U.S. investment plan highlight how BMS is building manufacturing capacity that can adjust to its evolving late-sta", "url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-us-2-3-151125664.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:11:25+00:00", "published_display": "12 Aug 2026 15:11", "sentiment": "neutral", "sentiment_pct": 49, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.171, "duplicate_count": 1, "topics": ["Balance Sheet", "Future Cash Flows", "Manufacturing", "Mergers", "Patent Expirations"]}, {"title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "summary": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:03:00+00:00", "published_display": "12 Aug 2026 15:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.129, "duplicate_count": 1, "topics": ["Earnings", "Guidance", "Obesity", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "How AstraZeneca\u2019s $400bn deal unravelled", "summary": "One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly \u00a34.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T04:00:28+00:00", "published_display": "12 Aug 2026 04:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.203, "duplicate_count": 1, "topics": []}, {"title": "1 Profitable Stock with Impressive Fundamentals and 2 We Avoid", "summary": "1 Profitable Stock with Impressive Fundamentals and 2 We Avoid While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies \u2014 as Jeff Bezos said, \"Your margin is my opportunity\". Profits are valuable, but they're not everything. At StockStory, we help you identify the companies that have real staying power. That said, here is one profitable company that generates reliable profits without sacrificing growth and two best left off your watchlist. Two Stocks to Sell: Wolverine Worldwide (WWW) Trailin", "url": "https://finance.yahoo.com/markets/stocks/articles/1-profitable-stock-impressive-fundamentals-024522358.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T02:45:22+00:00", "published_display": "12 Aug 2026 02:45", "sentiment": "positive", "sentiment_pct": 57, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.284, "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Financials", "Free Cash Flow", "Healthcare", "Return On Equity"]}, {"title": "AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn\u2019t Buy This Merger Talk", "summary": "AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti", "url": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:34:45+00:00", "published_display": "11 Aug 2026 19:34", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.211, "duplicate_count": 1, "topics": ["M A", "Oncology", "Patent Expiry", "Pharma", "Split"]}, {"title": "Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals", "summary": "During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has been replaced by the Trump era of almost non-existent antitrust enforcement. Most companies don't believe this moment can last, so they're taking advantage of it to make deals. When the summer's over, I believe we're going to come back to see ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T05:43:32+00:00", "published_display": "11 Aug 2026 05:43", "sentiment": "positive", "sentiment_pct": 84, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.161, "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Earnings Report", "Financial Results", "Financials", "Fourth Quarter"]}, {"title": "IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum", "summary": "Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while valuation and weak Zacks Style Scores temper the case for simply extrapolating the recent move. IMCR's 3-Month Rally Puts Growth in Focus IMCR shares have climbed more than 20% over the past 12 weeks. That compares with gains of 6.4% over four weeks and 0.6% over one week, making the longer recent advan", "url": "https://finance.yahoo.com/markets/stocks/articles/imcr-jumps-21-2-3-161600739.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T16:16:00+00:00", "published_display": "10 Aug 2026 16:16", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.189, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Price Target"]}, {"title": "Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?", "summary": "Immunocore Holdings plc IMCR offers a clear trade-off between commercial momentum and valuation risk. Kimmtrak continues to expand in metastatic uveal melanoma, while late-stage studies could open larger markets. The counterweight is equally clear. IMCR relies on one marketed product, trades above key industry valuation benchmarks and has seen a sharp deterioration in current-year earnings estimates. IMCR's Kimmtrak Growth Supports the Bull Case Second-quarter 2026 revenues rose 18.3% year over year to $115.9 million, driven by higher Kimmtrak volumes in the United States and international mar", "url": "https://finance.yahoo.com/healthcare/articles/imcr-worth-buying-kimmtrak-growth-154100947.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:41:00+00:00", "published_display": "10 Aug 2026 15:41", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.195, "duplicate_count": 1, "topics": ["Earnings", "Oncology", "Pharma", "Price Target"]}, {"title": "IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss", "summary": "Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of 1 cent. Kimmtrak remained the central growth driver, while a temporary U.S. distributor stocking benefit complicates the third-quarter setup. Higher research spending and a sizable cash balance also frame the company's push to broaden its melanoma opportunity. IMCR's Q2 Sales Beat Shows Kimmtrak Strength Kimmtrak generated $74.9 mill", "url": "https://finance.yahoo.com/healthcare/articles/imcr-q2-revenues-climb-18-153900256.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:39:00+00:00", "published_display": "10 Aug 2026 15:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.188, "duplicate_count": 1, "topics": ["Consensus Estimate", "Earnings", "Melanoma", "Pharma", "Ratings"]}, {"title": "BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?", "summary": "Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. BMY Outperforms Industry, Sector & S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research The company reported better-than-expected second-quarter results on July 30, supported by robust demand for Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag. Results were also boosted by strong Eliquis performan", "url": "https://finance.yahoo.com/healthcare/articles/bmy-rallies-16-2-three-151500081.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:15:00+00:00", "published_display": "10 Aug 2026 15:15", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.171, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Generic Competition", "Guidance", "Immuno Oncology"]}, {"title": "Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months", "summary": "Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader pipeline. The rally has been driven primarily by a series of positive regulatory developments that substantially reduced uncertainty surrounding RP1's path to commercialization. FDA Approves REPL's RP1 for Advanced Melanoma Earlier this month, the FDA granted accelerated approval to RP1 (vusolimogene oderparepvec) under the brand name Tudriqev, in combination", "url": "https://finance.yahoo.com/healthcare/articles/heres-why-replimune-stock-skyrockets-141700559.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:17:00+00:00", "published_display": "10 Aug 2026 14:17", "sentiment": "positive", "sentiment_pct": 88, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.241, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Earnings Per Share", "Fda Approval", "Oncology", "Regulation"]}, {"title": "Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas", "summary": "New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS' $40 Billion Commitment to American Innovation, Manufacturing and Economic Growth PRINCETON, N.J., August 10, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced the selection of Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients. The campus, at Generation Park in", "url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-squibb-advances-u-130100587.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T13:01:00+00:00", "published_display": "10 Aug 2026 13:01", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.228, "duplicate_count": 1, "topics": ["Biopharmaceutical", "Financial Results", "Innovation", "Manufacturing", "Pharma"]}, {"title": "CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong", "summary": "Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due to higher SG&A expenses tied to costs associated with the commercial launch of Myqorzo and lower revenues. Revenues amounted to $28.6 million, which went down from $66.8 million in the year-ago quarter but surpassed the Zacks Consensus Estimate of $20 million. Cytokinetics' shares have surged 28.1% year to date compared with the ind", "url": "https://finance.yahoo.com/healthcare/articles/cytk-q2-earnings-top-estimates-182200106.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T18:22:00+00:00", "published_display": "07 Aug 2026 18:22", "sentiment": "neutral", "sentiment_pct": 48, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.06, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Fourth Quarter", "Pharma"]}], "by_tier": {"direct": [{"title": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?", "summary": "Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio \u2014 including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy \u2014 is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r", "url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T18:36:00+00:00", "published_display": "12 Aug 2026 18:36", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.246, "duplicate_count": 1, "topics": ["Immuno Oncology", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "Is Bristol Myers\u2019 US$2.3 Billion Houston Manufacturing Campus Altering The Investment Case For BMY?", "summary": "Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about 2,000 construction and indirect roles through 2030. This facility's flexible, automation-ready design and alignment with the company's broader US$40.00 billion U.S. investment plan highlight how BMS is building manufacturing capacity that can adjust to its evolving late-sta", "url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-us-2-3-151125664.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:11:25+00:00", "published_display": "12 Aug 2026 15:11", "sentiment": "neutral", "sentiment_pct": 49, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.171, "duplicate_count": 1, "topics": ["Balance Sheet", "Future Cash Flows", "Manufacturing", "Mergers", "Patent Expirations"]}, {"title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "summary": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:03:00+00:00", "published_display": "12 Aug 2026 15:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.129, "duplicate_count": 1, "topics": ["Earnings", "Guidance", "Obesity", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "How AstraZeneca\u2019s $400bn deal unravelled", "summary": "One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly \u00a34.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T04:00:28+00:00", "published_display": "12 Aug 2026 04:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.203, "duplicate_count": 1, "topics": []}, {"title": "1 Profitable Stock with Impressive Fundamentals and 2 We Avoid", "summary": "1 Profitable Stock with Impressive Fundamentals and 2 We Avoid While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies \u2014 as Jeff Bezos said, \"Your margin is my opportunity\". Profits are valuable, but they're not everything. At StockStory, we help you identify the companies that have real staying power. That said, here is one profitable company that generates reliable profits without sacrificing growth and two best left off your watchlist. Two Stocks to Sell: Wolverine Worldwide (WWW) Trailin", "url": "https://finance.yahoo.com/markets/stocks/articles/1-profitable-stock-impressive-fundamentals-024522358.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T02:45:22+00:00", "published_display": "12 Aug 2026 02:45", "sentiment": "positive", "sentiment_pct": 57, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.284, "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Financials", "Free Cash Flow", "Healthcare", "Return On Equity"]}, {"title": "AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn\u2019t Buy This Merger Talk", "summary": "AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti", "url": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:34:45+00:00", "published_display": "11 Aug 2026 19:34", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.211, "duplicate_count": 1, "topics": ["M A", "Oncology", "Patent Expiry", "Pharma", "Split"]}, {"title": "Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals", "summary": "During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has been replaced by the Trump era of almost non-existent antitrust enforcement. Most companies don't believe this moment can last, so they're taking advantage of it to make deals. When the summer's over, I believe we're going to come back to see ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T05:43:32+00:00", "published_display": "11 Aug 2026 05:43", "sentiment": "positive", "sentiment_pct": 84, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.161, "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Earnings Report", "Financial Results", "Financials", "Fourth Quarter"]}, {"title": "IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum", "summary": "Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while valuation and weak Zacks Style Scores temper the case for simply extrapolating the recent move. IMCR's 3-Month Rally Puts Growth in Focus IMCR shares have climbed more than 20% over the past 12 weeks. That compares with gains of 6.4% over four weeks and 0.6% over one week, making the longer recent advan", "url": "https://finance.yahoo.com/markets/stocks/articles/imcr-jumps-21-2-3-161600739.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T16:16:00+00:00", "published_display": "10 Aug 2026 16:16", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.189, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Price Target"]}, {"title": "Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?", "summary": "Immunocore Holdings plc IMCR offers a clear trade-off between commercial momentum and valuation risk. Kimmtrak continues to expand in metastatic uveal melanoma, while late-stage studies could open larger markets. The counterweight is equally clear. IMCR relies on one marketed product, trades above key industry valuation benchmarks and has seen a sharp deterioration in current-year earnings estimates. IMCR's Kimmtrak Growth Supports the Bull Case Second-quarter 2026 revenues rose 18.3% year over year to $115.9 million, driven by higher Kimmtrak volumes in the United States and international mar", "url": "https://finance.yahoo.com/healthcare/articles/imcr-worth-buying-kimmtrak-growth-154100947.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:41:00+00:00", "published_display": "10 Aug 2026 15:41", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.195, "duplicate_count": 1, "topics": ["Earnings", "Oncology", "Pharma", "Price Target"]}, {"title": "IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss", "summary": "Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of 1 cent. Kimmtrak remained the central growth driver, while a temporary U.S. distributor stocking benefit complicates the third-quarter setup. Higher research spending and a sizable cash balance also frame the company's push to broaden its melanoma opportunity. IMCR's Q2 Sales Beat Shows Kimmtrak Strength Kimmtrak generated $74.9 mill", "url": "https://finance.yahoo.com/healthcare/articles/imcr-q2-revenues-climb-18-153900256.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:39:00+00:00", "published_display": "10 Aug 2026 15:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.188, "duplicate_count": 1, "topics": ["Consensus Estimate", "Earnings", "Melanoma", "Pharma", "Ratings"]}, {"title": "BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?", "summary": "Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. BMY Outperforms Industry, Sector & S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research The company reported better-than-expected second-quarter results on July 30, supported by robust demand for Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag. Results were also boosted by strong Eliquis performan", "url": "https://finance.yahoo.com/healthcare/articles/bmy-rallies-16-2-three-151500081.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:15:00+00:00", "published_display": "10 Aug 2026 15:15", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.171, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Generic Competition", "Guidance", "Immuno Oncology"]}, {"title": "Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months", "summary": "Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader pipeline. The rally has been driven primarily by a series of positive regulatory developments that substantially reduced uncertainty surrounding RP1's path to commercialization. FDA Approves REPL's RP1 for Advanced Melanoma Earlier this month, the FDA granted accelerated approval to RP1 (vusolimogene oderparepvec) under the brand name Tudriqev, in combination", "url": "https://finance.yahoo.com/healthcare/articles/heres-why-replimune-stock-skyrockets-141700559.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:17:00+00:00", "published_display": "10 Aug 2026 14:17", "sentiment": "positive", "sentiment_pct": 88, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.241, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Earnings Per Share", "Fda Approval", "Oncology", "Regulation"]}, {"title": "Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas", "summary": "New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS' $40 Billion Commitment to American Innovation, Manufacturing and Economic Growth PRINCETON, N.J., August 10, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced the selection of Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients. The campus, at Generation Park in", "url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-squibb-advances-u-130100587.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T13:01:00+00:00", "published_display": "10 Aug 2026 13:01", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.228, "duplicate_count": 1, "topics": ["Biopharmaceutical", "Financial Results", "Innovation", "Manufacturing", "Pharma"]}, {"title": "CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong", "summary": "Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due to higher SG&A expenses tied to costs associated with the commercial launch of Myqorzo and lower revenues. Revenues amounted to $28.6 million, which went down from $66.8 million in the year-ago quarter but surpassed the Zacks Consensus Estimate of $20 million. Cytokinetics' shares have surged 28.1% year to date compared with the ind", "url": "https://finance.yahoo.com/healthcare/articles/cytk-q2-earnings-top-estimates-182200106.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T18:22:00+00:00", "published_display": "07 Aug 2026 18:22", "sentiment": "neutral", "sentiment_pct": 48, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.06, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Fourth Quarter", "Pharma"]}], "industry": [], "sector": []}, "total_fetched": 14, "total_unique": 14, "total_relevant": 14, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 14, "unique_stories": 14, "duplicates_removed": 0, "relevant_stories": 14, "current_evidence": 14, "direct_evidence": 14, "eodhd_articles": 14, "eodhd": {"configured": true, "status": "healthy", "calls_used": 200, "call_budget": 500, "budget_used_pct": 40.0, "requests_made": 40, "last_success_at": "2026-08-13T05:45:20.147420+00:00", "newest_seen_at": "2026-08-13T05:26:00+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3383, "unmapped_mentions": 1799}, "status": "healthy"}, "sentiment_summary": {"positive": 10, "negative": 1, "neutral": 3, "score": 66, "raw_score": 70, "total": 14, "evidence_count": 14, "effective_articles": 13.01, "direct_story_count": 14, "industry_story_count": 0, "sector_story_count": 0, "story_count": 14, "source_count": 1, "source_concentration": 1.0, "direct_share": 100, "dispersion": 17, "confidence": 79, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T18:36:00+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 80, "events": [{"event": "earnings", "label": "Earnings", "weight": 4.8, "count": 8}, {"event": "deals", "label": "Deals and strategy", "weight": 2.4, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 0.6, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.6, "count": 1}], "positive_events": 10, "negative_events": 1, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 14, "unique_stories": 14, "duplicates_removed": 0, "relevant_stories": 14, "current_evidence": 14, "direct_evidence": 14, "eodhd_articles": 14, "eodhd": {"configured": true, "status": "healthy", "calls_used": 200, "call_budget": 500, "budget_used_pct": 40.0, "requests_made": 40, "last_success_at": "2026-08-13T05:45:20.147420+00:00", "newest_seen_at": "2026-08-13T05:26:00+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3383, "unmapped_mentions": 1799}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 55.83, "latest_week": "2026-08-07", "one_week_move": -0.6, "four_week_move": 11.2, "twelve_week_move": 15.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.038452, "market_dynamics_buy_signal": false, "relative_strength": 12.211371, "fair_value_gap": 26.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.2682, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.6% over one week, +11.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 14}], "tiers": [{"label": "Direct company coverage", "count": 14}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 8}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "66/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "79/100", "tone": "positive", "text": "13.01 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "14", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "17/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.6% over one week, +11.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?"}], "updated_at": "2026-08-13T05:59:59.329825+00:00", "detail_intelligence": {"headline": "Balanced read", "summary": "Constructive news tone is drawn from 14 fresh independent stories, including 14 company-specific items across 1 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 66, "display": "66", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 79, "display": "79", "tone": "positive", "note": "solid confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "14 direct stories"}, {"label": "Evidence agreement", "value": 83, "display": "83", "tone": "positive", "note": "17/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 100, "note": "12.91 effective stories"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 74, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 83, "note": "cross-story consistency"}, {"label": "Source independence", "value": 0, "note": "lower publisher concentration"}], "freshness": 74, "source_independence": 0, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 1, "score": 48, "tone": "neutral", "x": 683.2, "y": 138.6, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 6, "score": 73, "tone": "positive", "x": 820.6, "y": 93.1, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 2, "score": 76, "tone": "positive", "x": 866.4, "y": 87.7, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-12", "label": "12 Aug", "count": 5, "score": 66, "tone": "positive", "x": 912.2, "y": 105.9, "volume_height": 43.3, "volume_y": 222.7}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "683.2,138.6 820.6,93.1 866.4,87.7 912.2,105.9", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Improving", "tone": "positive", "recent_score": 70, "prior_score": 48, "delta": 22, "recent_count": 13, "prior_count": 1, "volume_delta": 12}, "freshness_buckets": [{"label": "Last 24 hours", "count": 3, "share": 21}, {"label": "1 to 3 days", "count": 10, "share": 71}, {"label": "4 to 7 days", "count": 1, "share": 7}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 14, "share": 100, "score": 70, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 8, "share": 57, "score": 69, "tone": "positive"}, {"label": "Deals and strategy", "count": 4, "share": 29, "score": 64, "tone": "positive"}, {"label": "Regulatory and legal", "count": 1, "share": 7, "score": 88, "tone": "positive"}, {"label": "Analyst action", "count": 1, "share": 7, "score": 73, "tone": "positive"}], "topics": [{"label": "Earnings", "count": 9, "share": 64}, {"label": "Pharma", "count": 7, "share": 50}, {"label": "Oncology", "count": 5, "share": 36}, {"label": "Biotech", "count": 4, "share": 29}, {"label": "Earnings Per Share", "count": 3, "share": 21}, {"label": "Revenue Growth", "count": 2, "share": 14}, {"label": "Price Target", "count": 2, "share": 14}, {"label": "Manufacturing", "count": 2, "share": 14}, {"label": "Immuno Oncology", "count": 2, "share": 14}, {"label": "Guidance", "count": 2, "share": 14}], "supporting": [{"label": "Direct evidence", "text": "14 current stories are mapped specifically to BRM."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 83/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?", "summary": "Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio \u2014 including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy \u2014 is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r", "url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T18:36:00+00:00", "published_display": "12 Aug 2026 18:36", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.291, "duplicate_count": 1, "topics": ["Immuno Oncology", "Oncology", "Pharma", "Revenue Growth"]}, "article_count": 14, "updated_at": "2026-08-13T04:53:47.325367+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 150.1, "label": "13 Feb 2026", "close": 50.52, "index": 100.0}, {"x": 78.6, "y": 146.4, "label": "20 Feb 2026", "close": 50.74, "index": 100.4}, {"x": 115.3, "y": 124.5, "label": "27 Feb 2026", "close": 52.05, "index": 103.0}, {"x": 151.9, "y": 143.1, "label": "06 Mar 2026", "close": 50.94, "index": 100.8}, {"x": 188.5, "y": 143.0, "label": "13 Mar 2026", "close": 50.95, "index": 100.8}, {"x": 225.1, "y": 174.3, "label": "20 Mar 2026", "close": 49.07, "index": 97.1}, {"x": 261.8, "y": 148.9, "label": "27 Mar 2026", "close": 50.59, "index": 100.1}, {"x": 298.4, "y": 130.7, "label": "03 Apr 2026", "close": 51.68, "index": 102.3}, {"x": 335.0, "y": 158.8, "label": "10 Apr 2026", "close": 50.0, "index": 99.0}, {"x": 371.7, "y": 144.4, "label": "17 Apr 2026", "close": 50.86, "index": 100.7}, {"x": 408.3, "y": 159.4, "label": "24 Apr 2026", "close": 49.96, "index": 98.9}, {"x": 444.9, "y": 134.5, "label": "01 May 2026", "close": 51.45, "index": 101.8}, {"x": 481.5, "y": 195.8, "label": "08 May 2026", "close": 47.78, "index": 94.6}, {"x": 518.2, "y": 184.8, "label": "15 May 2026", "close": 48.44, "index": 95.9}, {"x": 554.8, "y": 138.0, "label": "22 May 2026", "close": 51.24, "index": 101.4}, {"x": 591.4, "y": 183.0, "label": "29 May 2026", "close": 48.55, "index": 96.1}, {"x": 628.1, "y": 169.4, "label": "05 Jun 2026", "close": 49.37, "index": 97.7}, {"x": 664.7, "y": 181.0, "label": "12 Jun 2026", "close": 48.67, "index": 96.3}, {"x": 701.3, "y": 204.2, "label": "19 Jun 2026", "close": 47.28, "index": 93.6}, {"x": 737.9, "y": 163.6, "label": "26 Jun 2026", "close": 49.71, "index": 98.4}, {"x": 774.6, "y": 157.6, "label": "03 Jul 2026", "close": 50.07, "index": 99.1}, {"x": 811.2, "y": 155.4, "label": "10 Jul 2026", "close": 50.2, "index": 99.4}, {"x": 847.8, "y": 89.7, "label": "17 Jul 2026", "close": 54.13, "index": 107.1}, {"x": 884.5, "y": 82.4, "label": "24 Jul 2026", "close": 54.57, "index": 108.0}, {"x": 921.1, "y": 55.8, "label": "31 Jul 2026", "close": 56.16, "index": 111.2}, {"x": 957.7, "y": 61.3, "label": "07 Aug 2026", "close": 55.83, "index": 110.5}], "sentiment_points": [{"x": 710.3, "y": 122.6, "label": "20 Jun 2026", "score": 54}, {"x": 712.6, "y": 124.5, "label": "21 Jun 2026", "score": 53}, {"x": 718.5, "y": 131.8, "label": "22 Jun 2026", "score": 49}, {"x": 721.5, "y": 120.8, "label": "22 Jun 2026", "score": 55}, {"x": 723.0, "y": 130.0, "label": "23 Jun 2026", "score": 50}, {"x": 739.1, "y": 131.8, "label": "26 Jun 2026", "score": 49}, {"x": 745.0, "y": 131.8, "label": "27 Jun 2026", "score": 49}, {"x": 748.9, "y": 130.0, "label": "28 Jun 2026", "score": 50}, {"x": 749.2, "y": 126.3, "label": "28 Jun 2026", "score": 52}, {"x": 761.7, "y": 131.8, "label": "30 Jun 2026", "score": 49}, {"x": 772.9, "y": 131.8, "label": "02 Jul 2026", "score": 49}, {"x": 797.9, "y": 135.5, "label": "07 Jul 2026", "score": 47}, {"x": 841.8, "y": 131.8, "label": "15 Jul 2026", "score": 49}, {"x": 858.8, "y": 131.8, "label": "19 Jul 2026", "score": 49}, {"x": 859.9, "y": 131.8, "label": "19 Jul 2026", "score": 49}, {"x": 864.1, "y": 131.8, "label": "20 Jul 2026", "score": 49}, {"x": 874.8, "y": 131.8, "label": "22 Jul 2026", "score": 49}, {"x": 876.4, "y": 131.8, "label": "22 Jul 2026", "score": 49}, {"x": 877.5, "y": 131.8, "label": "22 Jul 2026", "score": 49}, {"x": 878.9, "y": 131.8, "label": "22 Jul 2026", "score": 49}, {"x": 881.0, "y": 131.8, "label": "23 Jul 2026", "score": 49}, {"x": 882.9, "y": 133.7, "label": "23 Jul 2026", "score": 48}, {"x": 884.1, "y": 133.7, "label": "23 Jul 2026", "score": 48}, {"x": 888.4, "y": 133.7, "label": "24 Jul 2026", "score": 48}, {"x": 896.2, "y": 131.8, "label": "26 Jul 2026", "score": 49}, {"x": 907.7, "y": 131.8, "label": "28 Jul 2026", "score": 49}, {"x": 917.8, "y": 130.0, "label": "30 Jul 2026", "score": 50}, {"x": 918.7, "y": 128.2, "label": "30 Jul 2026", "score": 51}, {"x": 921.9, "y": 120.8, "label": "31 Jul 2026", "score": 55}, {"x": 923.9, "y": 122.6, "label": "31 Jul 2026", "score": 54}, {"x": 926.6, "y": 122.6, "label": "01 Aug 2026", "score": 54}, {"x": 934.6, "y": 122.6, "label": "02 Aug 2026", "score": 54}, {"x": 944.4, "y": 130.0, "label": "04 Aug 2026", "score": 50}, {"x": 958.0, "y": 131.8, "label": "07 Aug 2026", "score": 49}], "price_path": "42.0,150.1 78.6,146.4 115.3,124.5 151.9,143.1 188.5,143.0 225.1,174.3 261.8,148.9 298.4,130.7 335.0,158.8 371.7,144.4 408.3,159.4 444.9,134.5 481.5,195.8 518.2,184.8 554.8,138.0 591.4,183.0 628.1,169.4 664.7,181.0 701.3,204.2 737.9,163.6 774.6,157.6 811.2,155.4 847.8,89.7 884.5,82.4 921.1,55.8 957.7,61.3", "sentiment_path": "710.3,122.6 712.6,124.5 718.5,131.8 721.5,120.8 723.0,130.0 739.1,131.8 745.0,131.8 748.9,130.0 749.2,126.3 761.7,131.8 772.9,131.8 797.9,135.5 841.8,131.8 858.8,131.8 859.9,131.8 864.1,131.8 874.8,131.8 876.4,131.8 877.5,131.8 878.9,131.8 881.0,131.8 882.9,133.7 884.1,133.7 888.4,133.7 896.2,131.8 907.7,131.8 917.8,130.0 918.7,128.2 921.9,120.8 923.9,122.6 926.6,122.6 934.6,122.6 944.4,130.0 958.0,131.8", "price_change": 10.5, "sentiment_change": -5, "latest_close": 55.83, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}